Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1360-0443.2012.03729.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of on-site CT-FFR analysis on cardiac photon-counting CT in evaluation of hemodynamically significant stenosis in comparison to invasive catheter angiography.
Eur J Radiol
January 2025
Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. Electronic address:
Objectives: Coronary CT angiography (CCTA) is an excellent tool in ruling out coronary artery disease (CAD) but tends to overestimate especially highly calcified plaques. To reduce diagnostic invasive catheter angiographies (ICA), current guidelines recommend CT-FFR to determine the hemodynamic significance of coronary artery stenosis. Photon-Counting Detector CT (PCCT) revolutionized CCTA and may improve CT-FFR analysis in guiding patients.
View Article and Find Full Text PDFDevelopment and Evaluation of a Food Choices Assessment Score (FCAS) Measuring the Healthfulness of Dietary Choices According to 2019 Canada's Food Guide/Canada's Dietary Guidelines, using the Canadian Health Measures Survey Food Frequency Questionnaire.
Appl Physiol Nutr Metab
January 2025
University of Toronto, Department of Nutritional Sciences, Toronto, Ontario, Canada;
The objective of this study was to develop and evaluate a Food Choices Assessment Score (FCAS) measuring alignment with 2019 Canada's Food Guide (CFG) and Canada's Dietary Guidelines (CDG) using a non-quantitative food frequency questionnaire (FFQ) data. Cross-sectional data from the Canadian Health Measures Survey (CHMS) (2016 to 2019), including 6,459 participants (≥19 years) and a non-quantitative FFQ (~100 food items) were used. Content and construct validity and assessing reliability were used to evaluate the FCAS, including a comparison of mean FCAS among Canadian subgroups, calculating the FCAS for high quality diet menus, investigating the consistency of the FCAS with the Dietary Approaches to Stop Hypertension (DASH), as a healthy diet linked with lower cardiometabolic risks, and estimating Cronbach's alpha for reliability.
View Article and Find Full Text PDFQuantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations.
Neurology
February 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Background And Objectives: Chronic kidney disease (CKD) is known to be associated with increased plasma phosphorylated tau217 (p-tau217) concentrations, potentially confounding the utility of plasma p-tau217 measurements as a marker of amyloid pathology in individuals with suspected Alzheimer disease (AD). In this study, we quantitatively investigate the relationship of plasma p-tau217 concentrations vs estimated glomerular filtration rate (eGFR) in individuals with CKD with and without amyloid pathology.
Methods: This was a retrospective examination of data from 2 observational cohorts from either the Mayo Clinic Study of Aging or the Alzheimer's Disease Research Center cohorts.
Comparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses.
J Bone Miner Res
January 2025
Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima-city, Fukushima, Japan.
This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period.
View Article and Find Full Text PDFAddition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.
J Manag Care Spec Pharm
January 2025
Abbott Diabetes Care, Mississauga, Ontario, Canada.
Background: Both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and continuous glucose monitoring (CGM) have been shown to improve glycated hemoglobin A1c (A1c) levels among patients with type 2 diabetes mellitus (T2DM). Recently, a US real-world study found statistically significant improvements in A1c levels among patients using GLP-1 RA and a CGM device, compared with a matched cohort receiving only GLP-1 RA.
Objectives: To assess the cost-effectiveness from a US payer perspective of initiating CGM (FreeStyle Libre Systems) in people living with T2DM using a GLP-1 RA therapy, compared with GLP-1 RA alone.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!